Clinical Trials
18
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
13
72.2%
Terminated
2
11.1%
Unknown
2
11.1%
Withdrawn
1
5.6%
No approval data available
- Theraclion's Sonovein® robotic platform for non-invasive varicose vein treatment has successfully passed China's GB 9706.1-2020 medical electrical equipment safety standard. - The certification validates Sonovein®'s compliance with stringent Chinese technical and safety criteria established by the National Medical Products Administration (NMPA). - This regulatory milestone represents significant progress toward market authorization in China, one of the world's largest markets for advanced medical technologies. - Sonovein® has already been adopted by more than a dozen centers worldwide and used in over 3,500 procedures.
- Theraclion has initiated clinical trials for SONOVEIN® 'SpeedPulse', a new feature that significantly reduces treatment time for varicose veins using high-intensity focused ultrasound technology. - The trial, launched in Prague in January 2025, integrates improved acoustics and therapeutic ultrasound pulsing, showing promising early results in treatment duration reduction. - Initial patient treatments demonstrate substantial potential for accelerating the non-invasive varicose vein procedure, enhancing SONOVEIN®'s competitiveness against traditional surgical methods.
- UVA Health is conducting a clinical trial to assess focused ultrasound's ability to enhance immunotherapy outcomes in melanoma patients undergoing surgery. - The trial combines focused ultrasound with PD-1 antibody blockade and Hiltinol injection to modify the tumor microenvironment and stimulate immune response. - Researchers will evaluate the safety and effectiveness of this combined approach by analyzing tissue destruction patterns and changes in the tumor's immune environment. - This study could provide vital insights into using focused ultrasound with immunotherapy for advanced melanoma and other solid tumors.
